Consequently, systemic delivery of a STING agonist combined with PARPi elicits robust anti-tumor immunity and demonstrates significant therapeutic efficacy in Brca1-deficient mouse models of breast cancer regardless of tumor cell-intrinsic STING expression. This evidence concerns the gene BRCA1 and breast carcinoma.